Avanos Medical (AVNS) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales from continuing operations rose to $172 million, up 2.6% organically year-over-year, driven by strong Digestive Health and improved Pain Management and Recovery performance.

• Adjusted diluted EPS was $0.34 and adjusted EBITDA reached $27 million, up 17% year-over-year, reflecting margin expansion and effective cost management.

• Transformation initiatives and cost discipline contributed to improved profitability and operating leverage.

• Net income from continuing operations was $4.3 million, reversing a $4.3 million loss in Q2 2023; adjusted net income reached $15.8 million.

• Completed divestiture of Respiratory Health business, focusing on core markets and ongoing transformation.

Financial highlights

• Net sales from continuing operations were $171.7 million; adjusted EBITDA was $26.8 million; adjusted diluted EPS was $0.34.

• Adjusted EBITDA grew 17% year-over-year; adjusted gross margin was 59.6%, stable versus prior periods.

• Free cash flow was $21.9 million, including a $15 million tax refund; significant improvement year-over-year.

• Cash and cash equivalents were $92.2 million as of June 30, 2024; total debt was $175.1 million.

• Adjusted operating profit was $21.8 million, up from $18.4 million year-over-year.

Outlook and guidance

• Reaffirmed 2024 guidance: revenue of $685–$705 million (mid-single digit organic growth), adjusted gross margin 59.5%–60.5%, SG&A 41%–42% of revenue.

• Adjusted diluted EPS expected between $1.30 and $1.45; adjusted EBITDA margin to improve by at least 200 basis points.

• Transformation Process expected to deliver $45–$55 million in gross savings by 2025, with most savings realized in 2024.

• 2025 targets: organic revenue ~$730 million, gross margin >60%, SG&A 38%–39%, free cash flow ~$100 million.

• Restructuring and transformation initiatives are anticipated to be substantially complete by the end of 2025.